Aliases & Classifications for Migraine with Aura

MalaCards integrated aliases for Migraine with Aura:

Name: Migraine with Aura 12 29 6 44 15 73
Migraine with Typical Aura 73
Classic Migraine 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10024
ICD10 33 G43.1 G43.109
ICD9CM 35 346.0
MeSH 44 D020325
NCIt 50 C117005
SNOMED-CT 68 155047002 4473006

Summaries for Migraine with Aura

Disease Ontology : 12 A migraine characterized by migraine headache which is preceded or accompanied by a transient focal neurological phenomenon.

MalaCards based summary : Migraine with Aura, also known as migraine with typical aura, is related to familial hemiplegic migraine and hemiplegic migraine, and has symptoms including headache An important gene associated with Migraine with Aura is FLNA (Filamin A), and among its related pathways/superpathways are cAMP signaling pathway and Calcium signaling pathway. The drugs Milnacipran and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, endothelial and cortex, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Migraine with Aura

Diseases in the Migraine with Aura family:

Migraine with Aura 7 Migraine with Aura 9

Diseases related to Migraine with Aura via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 119)
# Related Disease Score Top Affiliating Genes
1 familial hemiplegic migraine 32.7 ATP1A2 CACNA1A NOTCH3 SCN1A
2 hemiplegic migraine 32.2 ATP1A2 CACNA1A NOTCH3 PRRT2 SCN1A
3 headache 31.4 ATP1A2 CACNA1A EDNRA SCN1A
4 familial or sporadic hemiplegic migraine 31.1 ATP1A2 CACNA1A PRRT2 SCN1A
5 sporadic hemiplegic migraine 31.0 ATP1A2 CACNA1A SCN1A
6 migraine without aura 30.5 ATP1A2 CACNA1A DRD2 KCNK18 MTHFR SCN1A
7 restless legs syndrome 30.3 CACNA1A DRD2 SLC6A3
8 ischemic optic neuropathy 29.6 ACE MTHFR NOS3
9 cerebrovascular disease 29.3 ACE MTHFR NOTCH3
10 migraine with or without aura 1 28.0 ATP1A2 CACNA1A DBH DRD2 EDNRA HTR1B
11 migraine with aura 7 12.2
12 migraine with aura 9 12.2
13 epilepsy, familial temporal lobe, 4 11.4
14 migraine, familial hemiplegic, 1 11.2
15 migraine, familial hemiplegic, 2 11.2
16 migraine, familial hemiplegic, 3 11.1
17 migraine with or without aura 13 11.1
18 hemiplegia 10.7 ATP1A2 CACNA1A SCN1A
19 periodic limb movement disorder 10.6 DRD2 HTR2C SLC6A4
20 torticollis 10.5 CACNA1A DRD2 PRRT2
21 psychosexual disorder 10.5 HTR2C SLC6A4
22 early-onset schizophrenia 10.5 DBH DRD2 SLC6A4
23 cerebritis 10.5
24 episodic ataxia 10.4 ATP1A2 CACNA1A PRRT2
25 cerebral atherosclerosis 10.4 ACE MTHFR
26 patent foramen ovale 10.4
27 depression 10.3
28 alcohol-induced mental disorder 10.3 DRD2 SLC6A3 SLC6A4
29 brunner syndrome 10.3 DBH HTR1B SLC6A4
30 alcoholic psychosis 10.2 DRD2 SLC6A3 SLC6A4
31 hemifacial spasm 10.2 MTHFR NOS3
32 borderline personality disorder 10.2 HTR1B HTR2C SLC6A4
33 pathological gambling 10.2 DRD2 SLC6A3 SLC6A4
34 atrial heart septal defect 10.2
35 vascular dementia 10.2 ACE MTHFR NOTCH3
36 arteriovenous malformation 10.1
37 endotheliitis 10.1
38 stuttering 10.1 DBH DRD2 SLC6A3
39 multiple system atrophy 1 10.1 DBH DRD2 SLC6A3
40 thrombophilia 10.1
41 renal artery disease 10.0 ACE NOS3
42 mood disorder 10.0 DRD2 HTR1B HTR2C SLC6A4
43 oppositional defiant disorder 10.0 DBH DRD2 SLC6A3 SLC6A4
44 aging 10.0
45 transient cerebral ischemia 10.0
46 cervicitis 10.0
47 aortic coarctation 10.0
48 cluster headache 10.0
49 hemicrania continua 10.0
50 aneurysm 10.0

Comorbidity relations with Migraine with Aura via Phenotypic Disease Network (PDN):


Hypertension, Essential Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Migraine with Aura:



Diseases related to Migraine with Aura

Symptoms & Phenotypes for Migraine with Aura

UMLS symptoms related to Migraine with Aura:


headache

GenomeRNAi Phenotypes related to Migraine with Aura according to GeneCards Suite gene sharing:

26 (show all 19)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.72 SLC6A4
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 9.72 INSR
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.72 MTHFR
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.72 MTHFR
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 9.72 INSR
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.72 MTHFR
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-187 9.72 SLC6A4
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.72 ATP1A2
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.72 INSR
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.72 MTHFR
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.72 ATP1A2
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.72 INSR SLC6A4 ATP1A2
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.72 INSR
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.72 INSR MTHFR SLC6A4 ATP1A2
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.72 SLC6A4
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.72 MTHFR
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 9.72 MTHFR
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.72 MTHFR SLC6A4
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.72 MTHFR

MGI Mouse Phenotypes related to Migraine with Aura:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.44 FLNA INSR HTR1B EDNRA HTR2C PRRT2
2 growth/size/body region MP:0005378 10.37 HTR2C FLNA INSR HTR1B EDNRA NOS3
3 homeostasis/metabolism MP:0005376 10.32 EDNRA HTR2C FLNA INSR NOS3 SLC6A3
4 mortality/aging MP:0010768 10.31 HTR2C FLNA INSR HTR1B EDNRA NOS3
5 cardiovascular system MP:0005385 10.3 EDNRA FLNA INSR HTR1B NOS3 SCN1A
6 endocrine/exocrine gland MP:0005379 10.25 EDNRA INSR HTR1B NOS3 SLC6A3 NOTCH3
7 nervous system MP:0003631 10.22 HTR2C FLNA INSR KCNK18 EDNRA PRRT2
8 immune system MP:0005387 10.16 EDNRA HTR2C FLNA INSR NOS3 NOTCH3
9 integument MP:0010771 10.13 EDNRA HTR2C SLC6A3 NOTCH3 MTHFR SLC6A4
10 muscle MP:0005369 10.11 HTR2C INSR HTR1B EDNRA NOS3 SLC6A3
11 adipose tissue MP:0005375 10.09 HTR2C INSR HTR1B NOS3 ACE DBH
12 normal MP:0002873 10 FLNA EDNRA NOS3 SCN1A SLC6A3 NOTCH3
13 reproductive system MP:0005389 9.93 FLNA INSR KCNK18 HTR1B NOS3 SCN1A
14 respiratory system MP:0005388 9.61 EDNRA FLNA INSR NOS3 SCN1A NOTCH3
15 skeleton MP:0005390 9.32 EDNRA FLNA HTR1B PRRT2 NOS3 NOTCH3

Drugs & Therapeutics for Migraine with Aura

Drugs for Migraine with Aura (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 133)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
4
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
5
Almotriptan Approved, Investigational Phase 4 154323-57-6, 181183-52-8 123606
6
Topiramate Approved Phase 4,Phase 3,Phase 2 97240-79-4 5284627
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
8 Adrenergic Agents Phase 4,Phase 2,Phase 3
9 Antidepressive Agents Phase 4
10 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Neurotransmitter Uptake Inhibitors Phase 4
12 Psychotropic Drugs Phase 4,Phase 2
13 Serotonin Agents Phase 4,Phase 3,Phase 2,Not Applicable
14 Serotonin Uptake Inhibitors Phase 4
15 Analgesics Phase 4,Phase 2,Phase 3,Not Applicable
16 Analgesics, Non-Narcotic Phase 4,Phase 2,Not Applicable
17 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2,Not Applicable
18 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Not Applicable
19 Antirheumatic Agents Phase 4,Not Applicable
20 Autonomic Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
21 Cyclooxygenase Inhibitors Phase 4,Not Applicable
22 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
23 Antiemetics Phase 4,Phase 3,Phase 1,Phase 2
24 Dopamine Agents Phase 4
25 Dopamine Antagonists Phase 4
26 Dopamine D2 Receptor Antagonists Phase 4
27 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
28 Ketorolac Tromethamine Phase 4
29 Anticonvulsants Phase 4,Phase 3,Phase 2
30 Anti-Obesity Agents Phase 4,Phase 3,Phase 2
31 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Early Phase 1
32 Protective Agents Phase 4,Phase 3,Phase 2,Early Phase 1
33 Adjuvants, Anesthesia Phase 4
34 Analgesics, Opioid Phase 4
35 Anesthetics Phase 4,Phase 3,Phase 1,Phase 2
36 Anesthetics, General Phase 4
37 Anesthetics, Intravenous Phase 4
38 Central Nervous System Depressants Phase 4,Phase 3,Phase 1,Phase 2
39 Narcotics Phase 4
40 Pharmaceutical Solutions Phase 4
41
Serotonin Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 50-67-9 5202
42
Sumatriptan Approved, Investigational Phase 3,Phase 2,Not Applicable 103628-46-2 5358
43
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
44
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
45
Promethazine Approved, Investigational Phase 3 60-87-7 4927
46
Eletriptan Approved, Investigational Phase 3 143322-58-1 77993
47
Rizatriptan Approved Phase 3 145202-66-0, 144034-80-0 5078
48
Angiotensin II Approved, Investigational Phase 2, Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
49
Candesartan cilexetil Approved Phase 2, Phase 3 145040-37-5 2540
50
Propranolol Approved, Investigational Phase 2, Phase 3,Phase 3 525-66-6 4946

Interventional clinical trials:

(show top 50) (show all 81)
# Name Status NCT ID Phase Drugs
1 Preventive Treatment of Episodic and Chronic Migraine Unknown status NCT01319825 Phase 4 milnacipran
2 Intravenous Ketorolac and Metoclopramide for Pediatric Migraine in the Emergency Department Completed NCT01596166 Phase 4 Ketorolac Tromethamine;Metoclopramide
3 Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine Completed NCT00210496 Phase 4 topiramate; almotriptan malate
4 Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache. Completed NCT00212810 Phase 4 Topiramate
5 Intravenous Metoclopramide in the Acute Treatment of Migraine: A Double-blind, Randomized, Placebo-controlled Trial Completed NCT02314351 Phase 4 Metoclopramide 10 mg;Placebo;Fentanyl
6 Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura Completed NCT00449540 Phase 3
7 Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment Completed NCT01814189 Phase 3 Sumatriptan+Promethazine (SPr)
8 Is Chiropractic Spinal Manipulative Therapy an Efficient Treatment Option for Migraine Completed NCT01741714 Phase 3
9 Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study Completed NCT01859481 Phase 3 Placebo;Eletriptan HBr 40 mg;Eletriptan HBr 80 mg
10 Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine Completed NCT00334178 Phase 3 Laxymig ER (drug)
11 Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache Completed NCT00471952 Phase 3 Maxalt 10mg MLT plus Caffeine 75mg;Maxalt 10mg MLT plus Placebo;Placebo + Placebo
12 Candesartan Versus Propranolol for Migraine Prevention Completed NCT00884663 Phase 2, Phase 3 Candesartan;propranolol;placebo
13 A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine Completed NCT00236509 Phase 3 topiramate
14 A Study of the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prevention of Migraine Completed NCT00236561 Phase 3 topiramate, propranolol
15 A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine Completed NCT00231595 Phase 3 topiramate
16 Oral ALLOD-2 vs. Its Components & vs. Placebo in the Acute Treatment of Migraine (ANODYNE-1) Completed NCT03061734 Phase 2, Phase 3 ALLOD-2;ALLOD-2H;Component A (regular dose);Component B;Placebo
17 Dose Comparison Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine Completed NCT00131443 Phase 2, Phase 3 Topiramate
18 Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention Completed NCT02456740 Phase 3 Erenumab;Placebo
19 Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention Completed NCT02483585 Phase 3 Erenumab;Placebo
20 Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura Unknown status NCT00877838 Phase 2 NXN-188;Placebo
21 Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine Unknown status NCT00285402 Phase 2 AST-726 Low dose;AST-726 High dose;AST-726 Placebo
22 Ibudilast in the Treatment of Medication Overuse Headache Unknown status NCT01317992 Phase 1, Phase 2 Ibudilast;Placebo
23 Tonabersat in the Prophylaxis of Migraine With Aura Completed NCT00332007 Phase 2 Tonabersat;Placebo
24 Study of NXN 188 for the Treatment of Migraine With Aura Completed NCT00920686 Phase 2 NXN-188;placebo;sumatriptan succinate
25 Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache Completed NCT00123201 Phase 2 Dronabinol MDI
26 Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache Completed NCT00534560 Phase 2 Tonabersat;Tonabersat;Placebo
27 Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache Completed NCT00311662 Phase 2 Tonabersat;Placebo
28 A Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine Completed NCT00158002 Phase 2 Topiramate
29 Botox Injection in Treatment of Chronic Migraine Completed NCT02259075 Phase 1, Phase 2 Botulinum Toxin Type A
30 Continuous Treatment Study of Topiramate in Migraine Participants Completed NCT01799590 Phase 2 Topiramate
31 A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention Completed NCT02066415 Phase 2 Placebo
32 A Dose-Finding Study of Topiramate (JNS019) in Participants With Migraine Completed NCT01081795 Phase 2 Topiramate;Placebo
33 A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention. Completed NCT02174861 Phase 2 Erenumab
34 Efficacy and Safety Study of E2007 in Migraine Prophylaxis Completed NCT00154063 Phase 2 E2007
35 Can DFN-15 Terminate Migraine With Allodynia? Recruiting NCT03472378 Phase 2 DFN-15
36 Treatment of Chronic Migraine Headaches. Recruiting NCT03220113 Phase 1, Phase 2
37 A Phase 2 Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention Active, not recruiting NCT01952574 Phase 2 Erenumab;Placebo
38 PRIMA PFO Migraine Trial Terminated NCT00505570 Phase 2
39 A Study of a Melatonin Receptor Agonist to Prevent Migraine Terminated NCT00739024 Phase 2 Ramelteon;Placebo
40 Efficacy of Sumatriptan With Naprosyn in Migraine With Aura Unknown status NCT00893594 Not Applicable sumatriptan with naprosyn;placebo
41 Functional MRI and MRA in Migraine With Aura Unknown status NCT01388894
42 Migraine and Endothelial Dysfunction Unknown status NCT01388699
43 Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI Unknown status NCT02202486
44 MIBRAIN - Migraine and the Brain: Consequences, Causes, and Vascular Interaction Unknown status NCT01803984
45 Retinal Nerve Fiber Layer Thickness Changes in Migraine: A Meta-Analysis of Case-control Studies Unknown status NCT02196532
46 Inflammatory Markers Identification in Migraine Patients Unknown status NCT01618201
47 Identification of Inflammatory Markers in Migraine Patients Unknown status NCT00969995
48 Brainstem Grey Matter and Cerebral Autoregulation in Migraine With Aura. Completed NCT02708797 Not Applicable
49 Women With Migraine With Aura Neuroimaging Study Completed NCT02047695
50 Partial Rebreathing in the Treatment of Migraine With Aura Completed NCT03472417 Not Applicable

Search NIH Clinical Center for Migraine with Aura

Cochrane evidence based reviews: migraine with aura

Genetic Tests for Migraine with Aura

Genetic tests related to Migraine with Aura:

# Genetic test Affiliating Genes
1 Migraine with Aura 29

Anatomical Context for Migraine with Aura

MalaCards organs/tissues related to Migraine with Aura:

41
Brain, Endothelial, Cortex, Testes, Bone, Heart, Pituitary

Publications for Migraine with Aura

Articles related to Migraine with Aura:

(show top 50) (show all 382)
# Title Authors Year
1
Migraine with aura and white matter lesions: new evidences. ( 29904841 )
2018
2
Polypharmacology approach against migraine with aura and brain edema for the development of an efficient inhibitor and its analogues. ( 29756582 )
2018
3
Time Course of Cerebral Perfusion Changes in Children with Migraine with Aura Mimicking Stroke. ( 29903927 )
2018
4
Migraine with aura and persistent foramen ovale. ( 29219954 )
2018
5
Migraine with Aura: Surface-Based Analysis of the Cerebral Cortex with Magnetic Resonance Imaging. ( 29962883 )
2018
6
Basilar Artery Lateral Displacement May Be Associated with Migraine with Aura. ( 29527186 )
2018
7
Frequency and clinical implications of hypercoagulability states in a cohort of patients with migraine with aura. ( 29904875 )
2018
8
Patent foramen ovale and migraine with aura in a retrospective analysis: age matters. ( 29904837 )
2018
9
Brain MRI in patients affected by migraine with aura: is there any cortical lesion? ( 29904858 )
2018
10
The conundrum of relationship between pain and visual pathway in migraine with aura. ( 29904849 )
2018
11
Alien hand syndrome and migraine with aura: A case report. ( 29504481 )
2018
12
Jamestown Canyon virus meningoencephalitis mimicking migraine with aura in a resident of Manitoba. ( 29507158 )
2018
13
Increased intrinsic brain connectivity between pons and somatosensory cortex during attacks of migraine with aura. ( 28240389 )
2017
14
Evidence for Plastic Processes in Migraine with Aura: A Diffusion Weighted MRI Study. ( 29387002 )
2017
15
Aspirin Prophylaxis for Migraine with Aura: An Observational Case Series. ( 29017164 )
2017
16
Migraine with aura white matter lesions: preliminary data on clinical aspects. ( 28527065 )
2017
17
Prospective testing of ICHD-3 beta diagnostic criteria for migraine with aura and migraine with typical aura in patients with transient ischemic attacks. ( 28372496 )
2017
18
Migraine with aura and white matter lesions: an MRI study. ( 28527087 )
2017
19
A Review of &amp;quot;Hormonal Contraceptives and Migraine With Aura - Is There Still a Risk?&amp;quot; ( 28128464 )
2017
20
Migraine with Aura or Sports-Related Concussion: Case Report, Pathophysiology, and Multidisciplinary Approach to Management. ( 28067735 )
2017
21
Explicit diagnostic criteria for transient ischemic attacks to differentiate it from migraine with aura. ( 28994605 )
2017
22
Foveal and Peripapillary Vascular Decrement in Migraine With Aura Demonstrated by Optical Coherence Tomography Angiography. ( 29059314 )
2017
23
Pediatric migraine with aura in an Italian case series. ( 28527089 )
2017
24
Effect of hypoxia on BOLD fMRI response and total cerebral blood flow in migraine with aura patients. ( 28686073 )
2017
25
A Case of Migraine With Aura Resolving on Warfarin But Not on Apixaban. ( 28960288 )
2017
26
Increased brainstem perfusion, but no blood-brain barrier disruption, during attacks of migraine with aura. ( 28430860 )
2017
27
A randomized controlled trial of acupressure as an adjunctive therapy to sodium valproate on the prevention of chronic migraine with aura. ( 28682918 )
2017
28
Recognizing CADASIL: a Secondary Cause of Migraine with Aura. ( 28281108 )
2017
29
Migraine with aura and screening for biologicalA thrombophilia. ( 29175257 )
2017
30
Magnetic resonance imaging in children presenting migraine with aura: Association of hypoperfusion detected by arterial spin labelling and vasospasm on MR angiography findings. ( 28738690 )
2017
31
The nitric oxide synthase inhibitor and serotonin-receptor agonist NXN-188 during the aura phase of migraine with aura: A randomized, double-blind, placebo-controlled cross-over study. ( 29913885 )
2017
32
Stromal Cell-Derived Factor-1 Alpha Is Decreased in Women With Migraine With Aura. ( 27238143 )
2016
33
Frequency of pediatric migraine with aura in a clinic-based sample. ( 26790850 )
2016
34
Transient Splenial Lesion of the Corpus Callosum Related to Migraine with Aura in a Pediatric Patient. ( 27526308 )
2016
35
Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial. ( 26908949 )
2016
36
The effect of 1A mg folic acid supplementation on clinical outcomes in female migraine with aura patients. ( 27339806 )
2016
37
Patent Foramen Ovale With Atrial Septal Aneurysm Is Strongly Associated With Migraine With Aura: A Large Observational Study. ( 27930349 )
2016
38
Relationship between primary restless legs syndrome and migraine with aura. ( 27523456 )
2016
39
Addenbrooke's cognitive examination test for brief cognitive assessment of adolescents suffering from migraine with aura. ( 27255917 )
2016
40
Rare Complications of Migraine With Aura. ( 27400397 )
2016
41
Hormonal Contraceptives and Migraine With Aura-Is There Still a Risk? ( 27774589 )
2016
42
High leptin levels are associated with migraine with aura. ( 27165492 )
2016
43
Can the border of migraine with aura be safely extended? ( 27152015 )
2016
44
De Novo Migraine With Aura After Surgical Repair of Aortic Coarctation. ( 27910096 )
2016
45
Migraine with aura and risk of silent brain infarcts and white matter hyperintensities: an MRI study. ( 27190013 )
2016
46
White matter lesion burden in migraine with aura may be associated with reduced cerebral blood flow. ( 27177583 )
2016
47
Efficacy of frovatriptan as compared to other triptans in migraine with aura. ( 25916333 )
2015
48
Statins for all: should patients who have migraine with aura be on a statin? ( 26500300 )
2015
49
Migraine with aura: which patients are most at risk of stroke? ( 26017513 )
2015
50
Reduced functional connectivity between salience and visual networks in migraine with aura. ( 25888585 )
2015

Variations for Migraine with Aura

ClinVar genetic disease variations for Migraine with Aura:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 DGUOK NM_080916.2(DGUOK): c.65C> T (p.Pro22Leu) single nucleotide variant Uncertain significance rs757962437 GRCh38 Chromosome 2, 73926975: 73926975
2 DGUOK NM_080916.2(DGUOK): c.65C> T (p.Pro22Leu) single nucleotide variant Uncertain significance rs757962437 GRCh37 Chromosome 2, 74154102: 74154102
3 DGUOK NM_080916.2(DGUOK): c.278G> A (p.Gly93Glu) single nucleotide variant Uncertain significance GRCh38 Chromosome 2, 73946741: 73946741
4 DGUOK NM_080916.2(DGUOK): c.278G> A (p.Gly93Glu) single nucleotide variant Uncertain significance GRCh37 Chromosome 2, 74173868: 74173868
5 FLNA GRCh37/hg19 Xq28(chrX: 153575976-153586768) copy number loss Pathogenic GRCh37 Chromosome X, 153575976: 153586768
6 EMD; FLNA GRCh37/hg19 Xq28(chrX: 153588672-153609996) copy number gain Pathogenic GRCh37 Chromosome X, 153588672: 153609996

Expression for Migraine with Aura

Search GEO for disease gene expression data for Migraine with Aura.

Pathways for Migraine with Aura

GO Terms for Migraine with Aura

Cellular components related to Migraine with Aura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.92 DRD2 EDNRA HTR1B HTR2C INSR KCNK18
2 caveola GO:0005901 9.54 ATP1A2 INSR NOS3
3 plasma membrane GO:0005886 9.53 ACE ATP1A2 CACNA1A DRD2 EDNRA FLNA
4 presynapse GO:0098793 9.26 CACNA1A PRRT2 SLC6A3 SLC6A4
5 membrane GO:0016020 10.19 ACE ATP1A2 CACNA1A DBH DRD2 EDNRA
6 integral component of membrane GO:0016021 10.03 ACE ATP1A2 CACNA1A DBH DRD2 EDNRA

Biological processes related to Migraine with Aura according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.92 CACNA1A DBH HTR1B HTR2C
2 response to ethanol GO:0045471 9.82 DRD2 HTR1B SLC6A3
3 glucose homeostasis GO:0042593 9.81 CACNA1A DBH INSR
4 response to hypoxia GO:0001666 9.8 DRD2 EDNRA MTHFR SLC6A4
5 memory GO:0007613 9.75 DBH INSR SLC6A4
6 response to pain GO:0048265 9.65 CACNA1A DBH
7 regulation of sodium ion transport GO:0002028 9.65 DRD2 NOS3
8 response to iron ion GO:0010039 9.65 DRD2 SLC6A3
9 visual learning GO:0008542 9.65 ATP1A2 DBH DRD2
10 negative regulation of cytosolic calcium ion concentration GO:0051481 9.63 ATP1A2 DRD2
11 behavioral response to ethanol GO:0048149 9.63 DBH DRD2
12 feeding behavior GO:0007631 9.63 DRD2 HTR1B HTR2C
13 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.62 DRD2 HTR1B
14 neurotransmitter biosynthetic process GO:0042136 9.61 SLC6A3 SLC6A4
15 prepulse inhibition GO:0060134 9.61 DRD2 SLC6A3
16 response to nicotine GO:0035094 9.61 ATP1A2 DRD2 SLC6A3
17 neuromuscular process controlling posture GO:0050884 9.6 PRRT2 SCN1A
18 G-protein coupled receptor internalization GO:0002031 9.59 DRD2 HTR1B
19 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.58 DRD2 FLNA
20 response to cocaine GO:0042220 9.58 DRD2 HTR1B SLC6A3
21 monoamine transport GO:0015844 9.57 SLC6A3 SLC6A4
22 behavior GO:0007610 9.56 HTR1B HTR2C
23 locomotory behavior GO:0007626 9.56 DBH DRD2 HTR2C SLC6A3
24 adenohypophysis development GO:0021984 9.55 DRD2 SLC6A3
25 dopamine catabolic process GO:0042420 9.54 DBH SLC6A3
26 blood vessel remodeling GO:0001974 9.54 ACE DBH NOS3
27 neuron-neuron synaptic transmission GO:0007270 9.52 CACNA1A DRD2
28 dopamine uptake involved in synaptic transmission GO:0051583 9.51 SLC6A3 SLC6A4
29 adult walking behavior GO:0007628 9.5 CACNA1A DRD2 SCN1A
30 vasoconstriction GO:0042310 9.33 EDNRA HTR1B SLC6A4
31 regulation of blood pressure GO:0008217 9.26 ACE ATP1A2 EDNRA NOS3
32 response to drug GO:0042493 9.1 DRD2 HTR1B HTR2C MTHFR SLC6A3 SLC6A4

Molecular functions related to Migraine with Aura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 obsolete signal transducer activity GO:0004871 9.55 DRD2 EDNRA FLNA HTR1B HTR2C
2 neurotransmitter:sodium symporter activity GO:0005328 9.4 SLC6A3 SLC6A4
3 dopamine binding GO:0035240 9.37 DRD2 SLC6A3
4 serotonin binding GO:0051378 9.32 HTR1B HTR2C
5 monoamine transmembrane transporter activity GO:0008504 9.26 SLC6A3 SLC6A4
6 drug binding GO:0008144 9.1 ACE ATP1A2 DRD2 HTR1B HTR2C SLC6A3
7 dopamine:sodium symporter activity GO:0005330 8.96 SLC6A3 SLC6A4

Sources for Migraine with Aura

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....